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Available online 16 June 2017Background: NOD2 and smoking are risk factors for Crohn's disease. We meta-analyzed NOD2-smoking interac-
tions in Crohn's disease (Phase 1), then explored the effect of age at diagnosis on NOD2-smoking interactions
(Phase 2).
Methods: Phase 1: MEDLINE and EMBASE were searched for studies (n = 18) providing data on NOD2 and
smoking in Crohn's disease. NOD2-smoking interactions were estimated using odds ratios (ORs) and 95% conﬁ-
dence intervals (CIs) calculated using random effects models. Phase 2: A case-only study compared the propor-
tion of smokers and carriers of the 1007 fs variant across ages at diagnosis (≤16, 17–40, N40 years).
Findings: Phase 1: Having ever smokedwas less common among carriers of the 1007 fs variant of NOD2 (OR 0.74,
95%CI:0.66–0.83). There was no interaction between smoking and the G908R (OR 0.96, 95%CI:0.82–1.13) or the
R702W variant (OR 0.89, 95%CI:0.76–1.05). Phase 2: The proportion of patients (n= 627) carrying the 1007 fs
variant decreased with age at diagnosis (≤16 years: 15%; 17–40: 12%; N40: 3%; p= 0.003). Smoking was more
common in older patients (≤16 years: 4%; 17–40: 48%; N40: 71%; p b 0.001).
Interpretation: The negative NOD2-smoking interaction in Crohn's disease is speciﬁc to the 1007 fs variant. How-
ever, opposing rates of this variant and smoking across age at diagnosis may explain this negative interaction.
© 2017 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
Crohn's disease
NOD2
Cigarette smoking
Gene-environment interactions
Age1. Introduction
Crohn's disease is a chronic inﬂammatory disease of the gastroin-
testinal tract believed to result from the interaction between geneticotide binding oligomerization
Reporting Items for Systematic
orphism.
e, University of Calgary, 3280
. This is an open access article underand environmental factors, leading to an inappropriate immune re-
sponse to intestinal microbes (Knights et al., 2013). However, identify-
ing reproducible gene-environment interactions in patients with
Crohn's disease remains elusive. Previous studies examining the ef-
fects of NOD2 (nucleotide binding oligomerization domain containing
2) on Crohn's disease focus on three single nucleotide polymorphisms
(SNPs): 1007fs, G908R, and R702W. Individuals with the 1007 fs var-
iant have a 4-fold increased odds of developing Crohn's disease,
while the G908R variant triples and the R702W variant doubles the
odds of Crohn's disease (Economou et al., 2004). Active and ex-
smokers both have an approximately 2-fold increase in the odds of de-
veloping Crohn's disease (Mahid et al., 2006).the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Crohn's disease, an interactive effect is not consistently demonstrated.
Some studies demonstrated a negative interaction between NOD2 and
smoking (de Diego et al., 2006; Helbig et al., 2012) while others failed
to demonstrate a signiﬁcant interaction (Mardini et al., 2005;
Mendoza et al., 2003). In part, this may be explained by age-speciﬁc ef-
fects of genetic and environmental factors. Genetic susceptibility may
play a larger role in patients with early-onset Crohn's disease (i.e., diag-
nosis before age 16) compared to those diagnosed later in life (i.e., after
age 40) (de Ridder et al., 2007). In contrast, patients with late-onset
Crohn's disease may have a greater cumulative exposure to environ-
mental factors (e.g., longer history of smoking) than those with early-
onset Crohn's disease.
The aim of this study was to systematically review and summarize
the current knowledge of NOD2-smoking interactions in Crohn's dis-
ease, including SNP-speciﬁc NOD2-smoking interactions, and carry out
a case-only study to explore the role of age at diagnosis on the associa-
tion between NOD2 and smoking.
2. Materials and Methods
2.1. Phase 1: Systematic Review and Meta-Analysis of NOD2-Smoking
Interactions
Because of small sample sizes, most prior studies on NOD2-smoking
interactions pooled the three most common NOD2 variants (1007fs,
G908R, R702W), treating each SNP as an equivalent risk allele for the
NOD2-smoking interactions. Consequently, we conducted a systematic
review and meta-analysis to separately evaluate the interaction be-
tween SNP-speciﬁcNOD2 variants and smoking in patientswith Crohn's
disease. The systematic review and meta-analysis was based on a pre-
determined protocol (Supplementary Table 1) and is reported in accor-
dance with the Preferred Reporting Items for Systematic Review and
Meta-Analyses (PRISMA) checklist (Moher et al., 2009).
2.1.1. Study Identiﬁcation and Selection.
MEDLINE (1946–November 2015) and EMBASE (1974–November
2015) were searched to identify observational studies that examined
both cigarette smoking andNOD2 variants in relation to anyCrohn's dis-
ease-related outcome (i.e., disease onset, prognosis, or phenotype). The
search strategy is provided in Supplementary Table 1. Studies were in-
cluded if they provided data on the interaction between a NOD2 variant
and smoking status in patients with Crohn's disease. Only studies
reporting on each SNP independently were included. Studies reporting
on the independent effects of cigarette smoking andNOD2were includ-
ed if data on the interaction between NOD2 and having ever smoked
could be obtained from study authors. Additionally, authors of studies
combining all SNPs in a single analysis were contacted to provide SNP-
speciﬁc data and/or additional data on smoking behaviors if not includ-
ed in their original publication.
References of included studies and relevant review articles were
hand searched. Conference proceedings frommajor gastroenterological
meetings (e.g., Digestive Diseases Week 2009–2015, American College
of Gastroenterology Annual Scientiﬁc Meeting 2010–2014, and Con-
gress of the European Crohn's and Colitis Organization 2011–2014)
are indexed in EMBASE andwere reviewed during the primary database
search. When multiple manuscripts provided data on the same cohort
of patients, the study providing the most complete data was included
in themeta-analysis; if comparable datawas presented, themost recent
manuscript was included. The search was not limited by language, ge-
ography, or date of publication.
All records identiﬁed from the database search were independently
screened by two study authors (MEK and SC). The full-text of selected
abstracts was reviewed by two study authors (MEK and JY). Disagree-
ments were resolved in consultation with a third author (GGK).2.1.2. Data Extraction
Two authors (MEK and JY) independently extracted data from eligi-
ble studies using a piloted data extraction form, including: study design,
quality, and location; variants of NOD2; deﬁnition of smoking and
source of smoking information (questionnaire, chart review, or inter-
view); source of cases; sample size; prevalence of smoking; NOD2 allele
frequency; and the interaction between each NOD2 variant and
smoking, either as contingency tables or odds ratios (ORs) and their cor-
responding 95% conﬁdence intervals (CIs).
2.1.3. Outcomes
Case-only studies are commonly used to study gene-environment in-
teractions (Thomas, 2010). We used all cases from identiﬁed studies to
examine NOD2-smoking interactions in patients with Crohn's disease.
We examined the association between ever smoking (current and for-
mer smoking) among individuals with a NOD2 variant as compared to
patients who were wild type. The analysis was based on smoking status
at the time of diagnosis or at study entry when smoking ‘at diagnosis’
was unavailable. Analyses were conducted for the three most common
NOD2 variants (1007fs, G908R, and R702W) independently.
The following a priori sensitivity analyses were conducted: (1) re-
moving studies with unclear deﬁnitions of smoking; (2) limiting analy-
ses to studies deﬁning smoking at diagnosis; and (3) limiting to studies
where all participants were non-Jewish and White.
2.1.4. Study Quality
The quality of included studies was assessed using a modiﬁed ver-
sion of theNewcastle-Ottawa Quality Assessment Scale that incorporat-
ed aspects of study quality relevant to case-only studies of gene-
environment interactions (Supplementary Table 1) (Wells et al.,
2017). This included themethods used to select cases andmisclassiﬁca-
tion bias (e.g., ascertainment of smoking status). The risk of bias due to
residual confounding could not be assessed because the assessment of
NOD2-smoking interactions was not the primary objective of most in-
cluded studies. Study quality was evaluated independently by two au-
thors (MEK and JY). Disagreements were resolved by consensus and
in consultation with a third author (GGK).
2.1.5. Statistical Analysis
Data were analyzed using the meta package in R version 3.3.2
(Schwarzer, 2017; R Core Team, 2016). ORs and corresponding 95%
CIs were calculated from contingency tables for each study based on
cases of Crohn's disease only, then pooled using random effects models
to account for expected heterogeneity across studies. The estimated ORs
reﬂect the odds of being a smoker among individuals with a NOD2mu-
tation relative to the odds of being a smoker among patients without a
NOD2mutation.
Heterogeneitywas assessed using the I2measure and theCochranQ-
statistic; p b 0.10 was considered statistically signiﬁcant. Variance be-
tween studies (τ2) was quantiﬁed using the DerSimonian-Laird estima-
tor. Publication bias was assessed using a visual inspection of funnel
plots. The Egger test was used to assess funnel plot asymmetry (Egger
et al., 1997).
2.2. Phase 2: Effect of Age at Diagnosis on NOD2-Smoking Interaction
We evaluated the hypothesis that the negative interaction between
the 1007 fs variant in NOD2 and cigarette smokingmay be explained by
the opposing prevalence of these factors across different ages at diagno-
sis. Based on the results of the meta-analysis we only evaluated the in-
teraction between the 1007 fs variant of NOD2 and smoking.
We conducted a case-only study in a cohort of patients with
Crohn's disease enrolled in the Alberta IBD Consortium. The Alberta
IBD Consortium recruited patients from tertiary care centers in Calga-
ry, Alberta (n = 324) and Edmonton, Alberta, Canada (n = 303) be-
tween 2007 and 2014. All genotyped patients with a completed
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chart reviews were completed on each patient with Crohn's disease
using a standardized electronic data extraction form to conﬁrm the di-
agnosis of Crohn's disease and establish the age at diagnosis. Diagnosis
of Crohn's disease was conﬁrmed using standard clinical, endoscopic,
radiologic, and histologic criteria (Lennard-Jones, 1989). A subset of
chart reviews (n = 20) was completed in duplicate to ensure consis-
tency across reviewers. Age at diagnosis was deﬁned a priori according
to the Montreal Classiﬁcation: A1 (≤16 years of age); A2 (17 to
40 years); and A3 (N40 years) (Silverberg et al., 2005; Satsangi,
2006). In order to account for population stratiﬁcation, only non-Jew-
ish Caucasian patients were included in the analysis.
A standardized environmental questionnaire was used to assess
smoking status of patients and included information on frequency,
timing, quitting, and duration of cigarette use. A research coordinator
facilitated the administration of the environmental questionnaire to en-
sure accuracy and completeness of data. Determination of smoking sta-
tus was blinded to NOD2 genotype. Ever smokers had smoked at least
one cigarette per day for at least one year prior to being diagnosed
and never smokers were lifelong non-smokers prior to diagnosis. Previ-
ous studies have shown retrospective recall of smoking habits have
been demonstrated to be valid (sensitivity: 92%; speciﬁcity: 98%)
(Wong et al., 2012).
DNA was extracted from venous blood of patients using the Qiagen
(Germantown, MD, USA) DNAeasy kit. Samples were then sent to BGI-
Shenzhen for processing. The 1007fs variant of NOD2 was genotyped
using a Goldengate platform (Illumina). DNA extraction and genotyping
was conducted without knowledge of the patient's smoking status. Car-
riers of the 1007fs variant were deﬁned as individuals who were either
homozygous or heterozygous for this variant of the NOD2 gene.
All statistical analyses were conducted using SAS Version 9.4 (Cary,
NC, USA). We used the Cochran-Armitage test for trend to determine
if the proportion of patients carrying the 1007fs variant and having
ever smoked changed with age at diagnosis, as well as to test for differ-
ences in the city of residence and sex of patients across age groups. Age
groups were determined a priori and based on the Montreal Classiﬁca-
tion (Silverberg et al., 2005; Satsangi, 2006).
To ensure the interaction between the 1007fs variant and smoking
was consistent with the ﬁndings of the meta-analysis, we calculated
the OR and 95% CI to estimate this interaction. This odds ratio compared
the odds of carrying the 1007fs SNP among ever smokers to the odds of
carrying the 1007 fs SNP (homozygotes for the risk allele and heterozy-
gotes) among never smokers.
This study was approved by the Conjoint Research Ethics Boards at
the University of Calgary and the University of Alberta. Signed informed
consent was obtained from all study participants.
3. Results
3.1. Phase 1: Systematic Review and Meta-Analysis of NOD2-Smoking
Interaction
The literature search yielded 248 records; 170 remained after re-
moving duplicates. An additional 53 studies were identiﬁed after
reviewing references of included studies and relevant review articles.
Four studies were eligible for inclusion (Supplementary Fig. 1) (de
Diego et al., 2006; Helbig et al., 2012; Mendoza et al., 2003; Mardini et
al., 2005). An additional 14 studies were included after obtaining SNP-
speciﬁc data from study authors (Ananthakrishnan et al., 2014;
Cleynen et al., 2013; Doecke et al., 2015; Giachino et al., 2004;
Henckaerts et al., 2009; Karban et al., 2011; Laghi et al., 2005; Lakatos
et al., 2005; Latiano, 2008; Nagy et al., 2005; Protic et al., 2008; Renda
et al., 2008; Sabate et al., 2008;Walker et al., 2004). One study providing
SNP-speciﬁc data was excluded from the analysis due to small cell sizes
(Lauriola et al., 2011). In total, 18 studies (9064 patients with Crohn's
disease) were included in the meta-analysis. Reasons for studyexclusion are outlined in Supplementary Table 2. The characteristics of
included studies are provided in Table 1. The risk of bias in included
studies is provided in Supplementary Table 3.
The 1007fs variant negatively interacted with having ever smoked
cigarettes (pooled OR 0.74, 95%CI 0.66 to 0.83, 18 studies; heterogeneity:
I2 = 0%, τ2 = 0, p=0.49; Fig. 1). Neither the G908R variant (pooled OR
0.96, 95%CI 0.82 to 1.13, 17 studies; heterogeneity: I2 = 0%, τ2 = 0, p=
0.54; Fig. 2) nor the R702Wvariant (OR 0.89, 95%CI 0.76 to 1.05, 18 stud-
ies; heterogeneity: I2 = 31%, τ2 = 0.03, p=0.10; Fig. 3) interacted with
cigarette smoking. Resultswere consistent in sensitivity analyses exclud-
ing studieswith unclear deﬁnitions of smoking (Supplementary Table 4)
andwhen limiting analyses to studieswhere smoking statuswas deﬁned
at diagnosis (Supplementary Table 5) and all participantswere non-Jew-
ish and White (Supplementary Table 6).
3.1.1. Publication Bias
There was no evidence of publication bias for the interaction be-
tween NOD2 and smoking, regardless of the SNP being analyzed
(1007fs: p=0.70; G908R: p=0.22; R702W: p=0.75) (Supplementa-
ry Fig. 2A–C).
3.2. Phase 2: Effect of Age at Diagnosis on NOD2-Smoking Interaction
We enrolled 627 patients with Crohn's disease who provided data
on smoking status at diagnosis, 1007 fsNOD2 genotype, and age at diag-
nosis (Table 2). The proportion of patients having ever smoked signiﬁ-
cantly increased with increasing age at diagnosis (p b 0.001 for trend).
Only 4% (4/91) of patients diagnosed under the age of 17 had ever
smoked, compared to 48% (203/426) of those diagnosed between 17
and 40 and 71% (78/110) of patients diagnosed after 40 years of age
(Table 2).
The proportion of patients carrying the 1007fs variant decreased sig-
niﬁcantly with increasing age at diagnosis (p=0.003 for trend). Fifteen
percent (14/91) of patients diagnosed before age 17 and 12% of patients
diagnosed between 17 and 40 were carriers of this variant, whereas 3%
of individuals diagnosed after 40 were carriers (3/110) (Table 2).
The odds of carrying a 1007fs variant were signiﬁcantly lower
among individuals who had ever smoked cigarettes compared to indi-
viduals who had never smoked (OR 0.49, 95% CI 0.27 to 0.86).
4. Discussion
We systematically reviewed the interaction between NOD2 and cig-
arette smoking in Crohn's disease by analyzing 18 studies with N9000
patients, including previously unpublished data from 14 studies. Our
pooled analyses demonstrated that the negative association between
NOD2 and cigarette smoking was speciﬁc to the 1007 fs variant. More-
over, our case-only study showed that the prevalence of both the
1007fs mutation and cigarette smoking vary across ages at diagnosis
such that with advancing age, the prevalence of the 1007 fs variant de-
creases and exposure to cigarette smoke increases. These ﬁndings may
explain inconsistencies between studies and the elusiveness of identify-
ing reproducible gene-environment interactions.
Our systematic review demonstrated that the majority of NOD2-
smoking studies were underpowered to detect an interaction; for ex-
ample, 10 identiﬁed studies included fewer than 300 participants (de
Diego et al., 2006; Giachino et al., 2004; Laghi et al., 2005; Mardini et
al., 2005; Mendoza et al., 2003; Protic et al., 2008; Renda et al., 2008;
Sabate et al., 2008; Walker et al., 2004; Nagy et al., 2005). Because of
these small samples, the three most common NOD2 variants (1007fs,
G908R, and R702W)were often combined. However, thismeta-analysis
conﬁrms that the NOD2-smoking interaction in Crohn's disease is SNP-
speciﬁc. Thus, combining SNPs to improve powermay not bemethodo-
logically sound.
The biological plausibility of a negative association between
smoking and the 1007 fs variant of NOD2 is unclear. However, the
Table 1
Characteristics of included studies.
Study Country Age at diagnosis; mean (sd), years NOD2 genotype frequenciesa Smoking statusb Timing of smoking Sample size
Ananthakrishnan et al. (2014) USA Median (Q1,Q3): 24 (18, 33) Homozygous: 7%
Heterozygous: 26%
Wild type: 67%
Current: 8%
Former: 30%
Never: 62%
At time of study 697c
Cleynen et al. (2013) Europe (7 countries) 26 (11) Homozygous: 10%
Heterozygous: 29%
Wild type: 62%
Current: 21%
Former: 27%
Never: 52%
At time of study 1528c
de Diego et al. (2006) Spain Ever smokers: 33(12)
Never smokers: 34 (16)
Range: 12 to 77 years
Carriers: 28%
Wild type: 72%
Ever: 70%
Never: 30%
At diagnosis 178
Doecke et al. (2015) Australia and New Zealand b16: 10%
16–40: 77%
N40: 13%
Homozygous: 9%
Heterozygous: 24%
Wild type: 67%
Current: 44%
Former: 46%
Never: 10%
At diagnosis 675d
Giachino et al. (2004) Italy b40: 77%
N40: 23%
Carrier: 33%
Wild type: 67%
Current: 35%
Former: 15%
Never: 50%
At time of study 184c
Helbig et al. (2012) Germany 26 (10) Carrier: 46%
Wild type: 54%
Current (diagnosis): 41%
Non-current (diagnosis): 59%
Ever (study): 58%
Never (study): 42%
At diagnosis (N= 1283)
At time of study (N= 1636)
1636
Henckaerts et al. (2009) Belgium Median (Q1, Q3): 24 (19, 32)
≤16: 18%
17–40: 71%
N40: 11%
Carriers: 45%
Wild type: 55%
Current: 64%
Former: 8%
Never: 27%
At diagnosis 755c,e
Karban et al. (2011) Israel 25 (12) Homozygous: 6%
Heterozygous: 26%
Wild type: 68%
Current: 24%
Former: 11%
Never: 65%
At time of study 453f
Laghi et al. (2005) Italy 35 (13) Carrier: 33%
Wild type: 67%
Ever: 53%
Never: 47%
At diagnosis 239
Lakatos et al. (2005) Hungary 37 (9) Homozygous: 10%
Heterozygous: 25%
Wild type: 65%
Current: 32%
Former: 9%
Never: 58%
At time of study 527
Latiano (2008) Italy 29 (15) Homozygous: 8%
Heterozygous: 26%
Wild type: 66%
Current: 33%
Former: 12%
Never: 55%
At time of study 763c
(continued on next page)
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Table 1 (continued)
Study Country Age at diagnosis; mean (sd), years NOD2 genotype frequenciesa Smoking statusb Timing of smoking Sample size
Mardini et al. (2005) USA Median (range): 22 (11 to 41) years G908R Heterozygous: 8%
G908R Wild type: 92%
1007 fs Homozygous: 2%
1007fs Heterozygous: 12%
1007 fs Wild type: 86%
R702W Homozygous: 1%
R702W Heterozygous: 17%
R702WWild type: 82%
Ever: 54%
Never: 46%
Unclear 202
Mendoza et al. (2003) Spain b40 years: 78%
≥40 years: 22%
Carrier: 33%
Wild type: 67%
Smokers: 54%
Non-smokersg: 46%
Unclear 204
Nagy et al. (2005) Hungary NOD2 carrier: 30
NOD2 wild type: 33h
Homozygous: 4%
Heterozygous: 30%
Wild type: 66%
Current: 50%
Former: 38%
Never: 12%
At time of study 74
Protic et al. (2008) Serbia Median (range): 26 (6, 59)
≤16 years: 12%
17–40 years: 72%
N40 years: 16%
Homozygous: 2%
Heterozygous: 34%
Wild type: 65%
Current: 22%
Former: 1%
Never: 77%
At time of study 131
Renda et al. (2008) Italy 30 (12) Homozygous: 6%
Heterozygous: 24%
Wild type: 69%
Current: 37%
Former: 14%
Never: 49%
At diagnosis 182c
Sabate et al. (2008) France 40 (14) Homozygous: 5%
Heterozygous: 30%
Wild type: 64%
Current: 42%
Former: 6%
Never: 52%
At diagnosis 239c
Walker et al. (2004) Scotland 28 (14)
Range: 5 to 76
Homozygous: 2%
Heterozygous: 22%
Wild type: 76%
Current: 22%
Former: 47%
Never: 30%
At time of study 228c
a Patients homozygous for aNOD2mutation, either carrying two copies of the samemutation or one copy of amutation and a copy of a differentmutation (i.e., compound heterozygotes). Heterozygotes had one copy of a risk allele and one copy of the
wild type allele. Wild type individuals had two copies of the normal allele. Carriers had at least one copy of the risk allele (i.e., homozygous or heterozygous). Genotype frequencies are expressed for all SNPs in the NOD2 gene unless otherwise noted.
b Current smokers are patients that are smoking cigarettes at present. Former smokers had smoked in the past, but were no longer smoking at the time that smoking statuswas determined. Never smokerswere lifetime non-smokers. Ever smokers
were patients that had smoked at some point (i.e., includes current and former smokers).
c NOD2-smoking data available on a subset of patients included in the study.
d Data obtained from study authors corresponded to the cohort from Brisbane, Australia (dataset 1). There were 675 patients in this dataset.
e Study was limited to patients without perianal disease at diagnosis.
f Data obtained from study authors corresponded to an updated (larger) cohort of patients.
g Smoking deﬁned in the manuscript as ‘smokers’ and ‘non-smokers’ and was unclear if ‘smokers’were ever smokers (i.e., current and former smokers) or current smokers only. Study was excluded in sensitivity analysis.
h Unclear if the age of study participants was presented as a mean or median.
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Fig. 1. Forest plot depicting the interaction between 1007fs variant of NOD2 and cigarette smoking in patients with Crohn's disease.
193M.E. Kuenzig et al. / EBioMedicine 21 (2017) 188–196complex interplay between the different NOD2 variants and cigarette
smoking, and their effects on dendritic cells may underlie the negative
interaction observed between smoking and the 1007 fs variant but notFig. 2. Forest plot depicting the interaction between G908R variant othe NOD2 variants (Butler et al., 2007; van Heel et al., 2005; Ueno et
al., 2014; Kramer et al., 2006). The 1007fs variant of NOD2 results in a
protein that is truncated in the region of NOD2 responsible forf NOD2 and cigarette smoking in patients with Crohn's disease.
Fig. 3. Forest plot depicting the interaction between R702W variant of NOD2 and cigarette smoking in patients with Crohn's disease.
194 M.E. Kuenzig et al. / EBioMedicine 21 (2017) 188–196intracellular detection of peptidoglycans on bacterial cell walls. The
G908R and R702W variants are single base substitutions that may also
alter the structure of NOD2. However, the functional impacts of each
variant are not known.
Alternatively, the negative relationship betweenNOD2 and smoking
may be explained by a methodological phenomenon. Our case-only
study examined the impact of age of onset on the interaction between
NOD2 and cigarette smoking in patients with Crohn's disease. Twenty
percent of NOD2 carriers were diagnosed prior to age 17, whereas
only 3% were diagnosed after age 40. In contrast, nearly three-quarters
of patients over the age of 40 at diagnosis had a history of smoking com-
pared to only 4% of those diagnosed under age 17. This inverse relation-
ship between NOD2 and smoking, across ages at diagnosis results in
minimal overlap of the two factors and may misleadingly appear as aTable 2
Characteristics of included patients.
Age at diagnosis
Characteristic Total A1 (≤16) A2 (17–40) A3 (N40) p-value
Total (N) 627 91 426 110
City
Calgary 324 (52%) 45 (49%) 218 (51%) 61 (55%) 0.87
Edmonton 303 (48%) 46 (51%) 208 (49%) 49 (45%)
Sex
Male 260 (41%) 50 (55%) 155 (36%) 55 (50%) 0.68
Female 367 (59%) 41 (45%) 271 (64%) 55 (50%)
NOD2 (1007fs), N (%)
Wild type 558 (89%) 77 (85%) 374 (88%) 107 (97%) 0.003
Carriera 69 (11%) 14 (15%) 52 (12%) 3 (3%)
Smoking status, N (%)
Ever 285 (46%) 4 (4%) 203 (48%) 78 (71%) b0.0001
Never 342 (54%) 87 (96%) 223 (52%) 32 (29%)
Abbreviations: Q1: 1st quartile (25th percentile); Q3: 3rd quartile (75th percentile).
a Carriers of the 1007 fs variant (heterozygous or homozygous) were compared to wild
type.gene-environment interaction. However, the negative interaction be-
tween NOD2 and smoking persists after adjusting for age at diagnosis
(Helbig et al., 2012). Supplementary Fig. 3 explains the bias introduced
by combining patientswith varying ages of diagnosis, resulting in a neg-
ative interaction.
Consistentwith prior studies, we analyzed theNOD2-smoking inter-
action in Crohn's disease using a case-only study design (Helbig et al.,
2012). The case-only design increases resource and statistical efﬁciency
to detect gene-environment interactions (Thomas, 2010). However,
there are some assumptions of case-only designs including: (1) the ab-
sence of population stratiﬁcation; and (2) the independence of the ge-
netic and environmental risk factor in the source population for the
cases (Liu et al., 2012; Pierce and Ahsan, 2010; Wang and Lee, 2008).
Bias due to population stratiﬁcation (i.e., confounding by ethnicity)
arises when studies combine different ethnic groupswith variable allele
frequencies and prevalence of exposure (Wang and Lee, 2008). Sensitiv-
ity analyses limited to studies where all patients were non-Jewish and
White were consistent with our main analyses. However, we were not
able to assess the interaction between NOD2 and smoking in other
ethnicities (e.g., African Americans) due to the paucity of studies. Sec-
ondly, we assumed gene-environment independence due to a prior
study that found no association between NOD2 and smoking in their
control population (Helbig et al., 2012) and NOD2 has not been identi-
ﬁed in genome-wide association studies of smoking behaviors
(Furberg et al., 2010).
The results of this study point to the importance of evaluating genet-
ic and environmental factors in sub-phenotypes of Crohn's disease. We
focused on age at diagnosis. However, the ﬁndings ofNOD2-smoking in-
teraction studies may be inﬂuenced by other disease phenotypes such
as disease location or disease behavior. Both NOD2 and smoking are as-
sociated with ileal Crohn's disease. In addition, ileal and colonic Crohn's
disease have been shown to be genetically distinct phenotypes (Cleynen
et al., 2016). Thus, our study provides one example of how phenotypic
characteristics may inﬂuence gene-environment interactions.
195M.E. Kuenzig et al. / EBioMedicine 21 (2017) 188–196Our study provides the most comprehensive review of NOD2-
smoking interactions in Crohn's disease, includes previously unpub-
lished data, and evaluates the impact of age at diagnosis on this interac-
tion. Nonetheless, limitations should be considered. Firstly, the
association between NOD2 and smoking was not adjusted for potential
confounders (e.g., age, family history). Also, the quality of the meta-
analysis was dependent on the quality of the individual studies that
were included. With regard to the case-only study we were limited by
sample size, which impeded our ability to calculate age-speciﬁc ORs
for the interaction between NOD2 and smoking and to investigate the
role of sub-phenotypes of Crohn's disease (i.e., disease location and
behavior).
Gene-environment interactions for Crohn's disease are difﬁcult to
identify. Ourmeta-analysis demonstrated that gene-environment inter-
action studies need to be designed to assess SNP-speciﬁc effects, such
that only 100 fs variant of NOD2 interacted with smoking. Moreover,
our case-only study showed that the negative interaction between the
1007fs variant ofNOD2 and smokingmay be inﬂuenced by the contrast-
ing prevalence of NOD2 and smoking across ages at diagnosis with
Crohn's disease. This is one example of how gene-environment interac-
tions may depend on sub-phenotypes of Crohn's disease. Thus, we sug-
gest that future gene-environment studies should be powered to assess
SNP-speciﬁc interactions and be designed to evaluate interactions in
speciﬁc phenotypes of patients with Crohn's disease.
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